A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study Abstract #2706

Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Aim(s): To validate this RGS procedure, tests on ex vivo specimens of tumors expressing somatostatin receptors as small-intestine neuroendocrine (SI-NET) were performed.
Materials and methods: We studied these tumors due to the high uptake of 90Y-DOTATOC, a beta- emitting radiotracer. Patients were enrolled according to the tumor Standard Uptake Value (SUV) and the expected Tumor to Non-tumor Ratio (TNR) estimated from 68Ga-DOTATOC PET/CT images. Five SI-NET patients were submitted to PET/CT and entero-CT scan, 2 weeks prior to surgery. Twenty-four hours before surgery, patients received 5 mCi of 90Y-DOTATOC.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana

To read results and conclusion, please login ...

Further abstracts you may be interested in

#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.
Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors: Bertani E, Chiappa A, Fazio N, Grana C, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone